Clinical Trials
153 trialsTrop2-targeted immunoPET Imaging of Solid Tumors
RenJi Hospital
Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Mayo Clinic
18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors
Peking University First Hospital
N01-A-PICIT-GT
Peking University People's Hospital
LONGEVITI
University of Alberta
A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer
Cancer Research UK
iCaRe2
University of Nebraska
Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
Stanford University
CER
Cancer Support Community, Research and Training Institute, Philadelphia
Germline Alterations of Tumor Susceptibility Genes in New York Cancer Patients
Memorial Sloan Kettering Cancer Center
ASAP
Avera McKennan Hospital & University Health Center
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients
M.D. Anderson Cancer Center
CHANCES
Institut Paoli-Calmettes
Paclitaxel Therapeutic Drug Monitoring in Cancer Patients
Wake Forest University Health Sciences
PRO-ACTIVE
Fondazione del Piemonte per l'Oncologia
BLESSED: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast
Aveni Foundation
Riluzole For Preventing Cognitive Dysfunction in Ca Pts Receiving Chemo (REFOCUS): Pilot Trial
University of California, Irvine
DETERMINE
Cancer Research UK
ONE TEAM
Duke University
An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of KT032 Cell Injection in Patients With Mesothelin-positive Advanced Solid Tumors.
Zhejiang University
SELECT-CAR-NK
Essen Biotech
EBNK-ST-001
Essen Biotech
IT-TCP POS
Azienda Ospedaliero-Universitaria di Parma
PREPARE
Institut Bergonié
RAF/MEK
Royal Marsden NHS Foundation Trust
Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors
University Health Network, Toronto
DETERMINE
Cancer Research UK
LIBERATE
University Health Network, Toronto
DETERMINE
Cancer Research UK
INOVOLINE
Hospices Civils de Lyon
IMPROVE
Memorial Sloan Kettering Cancer Center
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
Hadassah Medical Organization
Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers
Hadassah Medical Organization
AOH1996 for the Treatment of Refractory Solid Tumors
City of Hope Medical Center
DECIDE
Institut Claudius Regaud
EARN
Washington University School of Medicine
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
GONGCHU Biotechnology Co., Ltd
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Jonsson Comprehensive Cancer Center
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
Cancer Research UK
Study of Paclitaxel Micelles for Injection in Chinese Patients With Advanced Solid Tumors.
First Affiliated Hospital of Zhejiang University
CNSI-Fe(II)
Sichuan Enray Pharmaceutical Sciences Company
AM-003
University of Virginia
Trial of Single Protein Encapsulated Doxorubicin, SPEDOX-6 in Advanced Malignancies
University of California, Irvine
PRIORITY
Institut Bergonié
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
University of California, Irvine
Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity Genetic Analysis Techniques
Yonsei University
EXODIAG
Centre Georges Francois Leclerc